Fertility startup Inito raises $29 million in Series B funding to scale up Home Health Diagnostic Platform And use AI-designed antibodies to unlock new types of home tests.
When the company launched its first fertility monitor in 2021, its goal was to make quantitative reproductive hormone testing possible at home.
While standard home ovulation tests predict fertile days by tracking estrogen and luteinizing hormone (LH), they do not measure the hormone that confirms your ovulation, which is the progesterone metabolite PDG. Inito allows women to measure estrogen, LH, progesterone (PDG), and FSH on a single test strip. Inito’s AI models interpret these levels to reveal reproductive hormone patterns, track fertile days, and confirm ovulation.
Fast forward to today, the startup has become a popular choice for women looking to track reproductive hormones, analyzing over 30 million reproductive hormone data points from 2021.
The startup is now doubling down on its belief that health care should start at home, and is working to grow Inito from a fertility tracker into a comprehensive hormone and at-home health diagnostics platform.
Inito is using the new funding to invest in and develop AI-engineered antibodies, which it says will allow the development of new types of tests and improve the accuracy of existing tests.
For reference, when you do testing in a lab or at home, antibodies are what bind to a target molecule (like estrogen or testosterone) to produce a signal. Traditional antibodies are grown inside animals and then manually tested in a laboratory, which can be a slow and expensive process. Traditional antibodies lack the sensitivity to perform at-home testing for a large number of biomarkers.
techcrunch event
san francisco
,
October 13-15, 2026
Ianito says AI-designed antibodies change the game. Instead of “growing” antibodies in animals, they can be treated almost like software.
“We predict how proteins fold in 3D, design synthetic antibodies using AI, and test millions of variants before even making one in the lab,” Varun A Venkatesan, co-founder and CTO of Inito, explained in an email. “This produces antibodies that are far more sensitive, consistent and stable than anything developed by traditional methods.”
For Inito, this will unlock the next generation of home tests. Venkatesan says the company is already using these methods in R&D and its wet-lab is showing promising results.
“The real vision is bigger than just adding new tests,” said Ayush Rai, co-founder and CEO of Inito. “The end game is to completely redefine diagnosis. If you want to understand what’s happening inside your body at every stage of life and health needs, you shouldn’t be limited by clinic appointments, lab schedules or rigid testing systems. You should be able to measure, track, and get information about your body from home with lab-grade confidence.”
Ianito wants to expand her approach beyond the “trying to conceive” platform. Its reader and app will soon power tests for pregnancy, menopause, and comprehensive home health monitoring.
“Our long-term roadmap goes far beyond fertility,” Rai said. “We are building toward a platform that can measure and interpret the full spectrum of hormones that shape health across the lifespan. Comprehensive endocrine markers like pregnancy progression, menopause, and testosterone – all powered by the AI antibodies and imaging that differentiate Inito today.”
The company is going to use a portion of the funding to scale up manufacturing and grow globally to meet growing demand in the United States and new international markets.
Inito’s latest funding round was led by Bertelsmann India Investments and Fireside Ventures. This investment brings Inito’s total funding to approximately $45 million. The company had previously raised $6 million led by Fireside Ventures and $9 million from Y Combinator, former Nurx CEO Varsha Rao, and a dozen physicians and family offices.
